COLL

Collegium Pharmaceutical, Inc. (COLL) | Rumor.io

Collegium Pharmaceutical

COLL

Attention (50-day avg)0%

Attention rank (50-day avg)#4,010

Bullish sentiment (50-day avg)100%

Price to earnings ratio17.7

Market capitalization701.5M

Earnings per share1.27

Dividend yield (TTM)—

Revenue (annual)780.6M

Net income (annual)62.9M

Social

What share of all stock conversation is about COLL?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% 0

Jul 2

Collegium Pharmaceutical ($COLL) generates significant free cash flow with 61% gross margins and trades at a multiple that implies the business is dying.
The company has a strong portfolio of patent-protected extended-release drugs for pain and ADHD, with revenue compounding ~20% for five years and protected by patents until 2037.
The enterprise trades around 5.6x owner earnings, with an intrinsic value estimated to be around $122 (a ~70% margin of safety) at the current price of ~$35.

Generated by AI

Sentiment

Of the messages about COLL that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	100% +15
Bearish	—	—	—	0% -15

Bullish· Feb 20

The asset has a strong potential for growth, with many users expecting it to reach $1 million.
The company is gaining a significant following, with users expressing excitement and enthusiasm for its future prospects.
The roadmap for the asset is seen as a key factor in its success, with users praising its potential and expressing confidence in the company's ability to execute its plans.

Bearish· Sep 14

The market may not care about Collegium Pharmaceutical's approval, making it an easy short.
The stock's illiquidity makes it a high-risk shorting opportunity.
The company's news may have a negative impact on Pernix Therapeutics' stock, specifically Zohydro.

Generated by AI

Topics

Of the messages about COLL that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	0%	38.17%
Technical Analysis	—	—	100%	56.49%
Analysts	—	—	0%	1.53%
Controversies	—	—	0%	1.53%
Earnings	—	—	0%	2.29%
Macro	—	—	0%	0%

Earnings· Aug 8

Collegium Pharmaceutical, Inc. ($COLL) beats EPS loss estimates by $0.02 and slightly beats on revenues.
$COLL reports FQ2 earnings of -15c EPS and $73.06M Revs, beating Estimize EPS Consensus by 25c and Revenue Consensus by $1.48M.
$COLL beats estimates with ($0.40) EPS and $73.10m revenue, with stock dropping 23% since last earnings report.

Analysts· Feb 15

HC Wainwright raises Collegium Pharmaceutical's price target to $29.00, citing the company's acquisition of BioDelivery Sciences International.
Needham & Company LLC raises Collegium Pharmaceutical's price target to $34.00, maintaining a Buy rating.
Cantor Fitzgerald upgrades Collegium Pharmaceuticals to "overweight" and raises its price target to $26.00, citing the same acquisition.

Announcements· Jul 29

Collegium Pharmaceutical ($COLL) to acquire Ironshore Therapeutics for $525M in cash, with a potential additional $25M commercial milestone payment.
The acquisition expands Collegium's reach into neurology, adding Jornay PM, a CNS stimulant for ADHD, to its portfolio.
Collegium reaffirms its annual sales forecast for 2024, maintaining a product revenue outlook of $580-595M, in line with market consensus.

Generated by AI

Community

Of the messages about COLL, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	0%	13.36%
Newcomers	—	—	100%	86.64%

Regulars· Feb 14

Collegium Pharmaceutical, Inc. ($COLL) has agreed to acquire BioDelivery Sciences International, Inc. ($BDSI) in an all-cash deal at $5.60 per share, totaling $604 million.
The acquisition is expected to broaden Collegium's pain portfolio, with BioDelivery Sciences' products complementing Collegium's existing offerings.
The deal has resulted in a 13.7% increase in Collegium's share price, with some analysts speculating that the takeover news has trapped short sellers.

Newcomers· Feb 14

Newcomers to the asset are focusing on the recent merger and acquisition deal between Collegium Pharmaceutical and BioDelivery Sciences, with many posts discussing the terms of the deal and its potential impact on the companies involved.
Some users are highlighting the significant price increase in BioDelivery Sciences' stock, with one user noting a 51% rise, while others are discussing the implications of the deal on the pain management market.
The acquisition deal is expected to close in late Q1 2022, with one user estimating a 40-45 day timeline based on similar situations, and another noting that the deal will provide a 54% premium to the closing price of BioDelivery Sciences on the day before the announcement.

Generated by AI

STOUGHTON, Mass., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading biopharmaceutical company focused on improving the lives of people living with serious and often misunderstood conditions, today announced that its management will participate in the following investor conferences: Morgan Stanley 24th Annual Global Healthcare ConferenceFireside Chat Date and Time: Tuesday, September 15, 2026, at 4:05 p.m. ETNew York, NY H.C. Wainwright 28th Annual Global

21d agoYahoo! Finance Canada

5 Revealing Analyst Questions From Collegium Pharmaceutical’s Q2 Earnings Call

Collegium Pharmaceutical’s second quarter saw sales growth, but results missed Wall Street’s revenue expectations, leading to a negative market reaction. Management attributed top-line growth to the expansion of its ADHD business, notably Jornay PM’s 41% year-over-year revenue increase and broader prescriber reach. CEO Vikram Karnani stressed that the integration of recently acquired Azstarys was completed ahead of the crucial back-to-school season, reinforcing the company’s strategy to diversif

1mo agoYahoo Finance

Collegium Pharmaceutical stock jumps on $50M share buyback

1mo agoInvesting.com

Collegium gains on accelerated share buybacks (COLL:NASDAQ)

Collegium Pharmaceutical (COLL) stock rises as the company annouces a $50M accelerated share repurchase agreement with Jefferies (JEF). Read more here.

1mo agoSeeking Alpha

Also Discussed

Investors talking about COLL also mention

#	Name	Attention
1	BYN - Banyan Acquisition Corporation	——
2	BDSI - BioDelivery Sciences International, Inc.	——
3	HZNP - Horizon Therapeutics Public Limited Company	——
4	GMS - GMS Inc.	——
5	BHG - Bright Health Group, Inc.	——
6	ITCI - Intra-Cellular Therapies, Inc.	——
7	Pacira BioSciences, Inc.PCRX	0%new
8	Natural Gas Services Group, Inc.NGS	0%new
9	Invesco BulletShares 2031 Corporate Bond ETFBSCV	0%0
10	Inspire Global Hope ETFBLES	0%new

Collegium Pharmaceutical, Inc.

Healthcare
Drug Manufacturers - Specialty & Generic

Collegium Pharmaceutical, Inc. is a specialty biopharmaceutical company focused on developing and commercializing medicines for pain management and attention-deficit/hyperactivity disorder (ADHD). Its current portfolio includes branded prescription products such as Xtampza ER, Belbuca, the Nucynta franchise, Jornay PM, and Symproic, serving patients with complex and chronic medical conditions. The company emphasizes differentiated drug-delivery technology and responsible pain-management therapies, with its business centered on the U.S. market. Collegium Pharmaceutical, Inc. also supports its products through commercial operations, market access, and patient support activities, making it a notable participant in branded specialty pharmaceuticals.

Website

Location

100 Technology Center Drive

Stoughton, MA, 02072

United States

Social

What share of all stock conversation is about COLL?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% 0

Jul 2

Collegium Pharmaceutical ($COLL) generates significant free cash flow with 61% gross margins and trades at a multiple that implies the business is dying.
The company has a strong portfolio of patent-protected extended-release drugs for pain and ADHD, with revenue compounding ~20% for five years and protected by patents until 2037.
The enterprise trades around 5.6x owner earnings, with an intrinsic value estimated to be around $122 (a ~70% margin of safety) at the current price of ~$35.

Generated by AI

Sentiment

Of the messages about COLL that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	100% +15
Bearish	—	—	—	0% -15

Bullish· Feb 20

The asset has a strong potential for growth, with many users expecting it to reach $1 million.
The company is gaining a significant following, with users expressing excitement and enthusiasm for its future prospects.
The roadmap for the asset is seen as a key factor in its success, with users praising its potential and expressing confidence in the company's ability to execute its plans.

Bearish· Sep 14

The market may not care about Collegium Pharmaceutical's approval, making it an easy short.
The stock's illiquidity makes it a high-risk shorting opportunity.
The company's news may have a negative impact on Pernix Therapeutics' stock, specifically Zohydro.

Generated by AI

Topics

Of the messages about COLL that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	0%	38.17%
Technical Analysis	—	—	100%	56.49%
Analysts	—	—	0%	1.53%
Controversies	—	—	0%	1.53%
Earnings	—	—	0%	2.29%
Macro	—	—	0%	0%

Earnings· Aug 8

Collegium Pharmaceutical, Inc. ($COLL) beats EPS loss estimates by $0.02 and slightly beats on revenues.
$COLL reports FQ2 earnings of -15c EPS and $73.06M Revs, beating Estimize EPS Consensus by 25c and Revenue Consensus by $1.48M.
$COLL beats estimates with ($0.40) EPS and $73.10m revenue, with stock dropping 23% since last earnings report.

Analysts· Feb 15

HC Wainwright raises Collegium Pharmaceutical's price target to $29.00, citing the company's acquisition of BioDelivery Sciences International.
Needham & Company LLC raises Collegium Pharmaceutical's price target to $34.00, maintaining a Buy rating.
Cantor Fitzgerald upgrades Collegium Pharmaceuticals to "overweight" and raises its price target to $26.00, citing the same acquisition.

Announcements· Jul 29

Collegium Pharmaceutical ($COLL) to acquire Ironshore Therapeutics for $525M in cash, with a potential additional $25M commercial milestone payment.
The acquisition expands Collegium's reach into neurology, adding Jornay PM, a CNS stimulant for ADHD, to its portfolio.
Collegium reaffirms its annual sales forecast for 2024, maintaining a product revenue outlook of $580-595M, in line with market consensus.

Generated by AI

Community

Of the messages about COLL, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	0%	13.36%
Newcomers	—	—	100%	86.64%

Regulars· Feb 14

Collegium Pharmaceutical, Inc. ($COLL) has agreed to acquire BioDelivery Sciences International, Inc. ($BDSI) in an all-cash deal at $5.60 per share, totaling $604 million.
The acquisition is expected to broaden Collegium's pain portfolio, with BioDelivery Sciences' products complementing Collegium's existing offerings.
The deal has resulted in a 13.7% increase in Collegium's share price, with some analysts speculating that the takeover news has trapped short sellers.

Newcomers· Feb 14

Newcomers to the asset are focusing on the recent merger and acquisition deal between Collegium Pharmaceutical and BioDelivery Sciences, with many posts discussing the terms of the deal and its potential impact on the companies involved.
Some users are highlighting the significant price increase in BioDelivery Sciences' stock, with one user noting a 51% rise, while others are discussing the implications of the deal on the pain management market.
The acquisition deal is expected to close in late Q1 2022, with one user estimating a 40-45 day timeline based on similar situations, and another noting that the deal will provide a 54% premium to the closing price of BioDelivery Sciences on the day before the announcement.

Generated by AI

Collegium Pharmaceutical

Social

Jul 2

Bullish· Feb 20

Bearish· Sep 14

Earnings· Aug 8

Analysts· Feb 15

Announcements· Jul 29

Regulars· Feb 14

Newcomers· Feb 14

Oppenheimer initiates Collegium Pharmaceutical stock at Outperform

Collegium Pharmaceutical at H.C. Wainwright: pushing beyond pain

Collegium to Participate in Upcoming Investor Conferences

5 Revealing Analyst Questions From Collegium Pharmaceutical’s Q2 Earnings Call

Collegium Pharmaceutical stock jumps on $50M share buyback

Collegium gains on accelerated share buybacks (COLL:NASDAQ)

Also Discussed

Collegium Pharmaceutical, Inc.

Company Information

Location

Oppenheimer initiates Collegium Pharmaceutical stock at Outperform

Collegium Pharmaceutical at H.C. Wainwright: pushing beyond pain

Collegium to Participate in Upcoming Investor Conferences

5 Revealing Analyst Questions From Collegium Pharmaceutical’s Q2 Earnings Call

Collegium Pharmaceutical stock jumps on $50M share buyback

Collegium gains on accelerated share buybacks (COLL:NASDAQ)

Also Discussed

Social

Jul 2

Bullish· Feb 20

Bearish· Sep 14

Earnings· Aug 8

Analysts· Feb 15

Announcements· Jul 29

Regulars· Feb 14

Newcomers· Feb 14